These are just 2 recent examples of many studies that aim to establish the yield, cost-effectiveness, and clinical utility of genetic testing in epilepsy. For example, Howell and colleagues13 evaluated diagnostic strategies in a population-based cohort of infants who present with epilepsy. They also found that gene panel sequencing is a cost-effective test, especially if done early in the diagnostic workup. Another study11 analyzed the cost-effectiveness of exome sequencing compared to a fairly comprehensive first-tier workup (including imaging, metabolic screening, CMA, gene panel) and found that exome sequencing early in the diagnostic process offers a cost savings.